Stock AnalizCentene Corp. CNC
Medical Specialities · data as of November 13, 2026
Centene Corp. (CNC) is a healthcare company listed in the US with a market value of about $35.3B. In the twelve months to September 30, 2026 it had revenue of $203.9B and net income of $1.5B, a net margin of 0.7%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 24.4, a price to free cash flow of 8.9, 5-year revenue growth of 12% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 14% above the current price.
Score: 2.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $203.9B | $194.8B | $163.1B | $154.0B | $144.5B | $126.0B | $111.1B | $74.6B | $60.1B | $48.4B | $40.6B |
| Net income | $1.5B | -$6.7B | $3.3B | $2.7B | $1.2B | $1.3B | $1.8B | $1.3B | $900M | $828M | $562M |
| Free cash flow | $3.9B | $4.3B | -$490M | $7.3B | $5.3B | $3.3B | $4.6B | $753M | $559M | $1.1B | $1.5B |
| EPS (diluted) | $2.92 | $-13.53 | $6.31 | $4.95 | $2.07 | $2.28 | $3.12 | $3.14 | $2.26 | $2.34 | $1.71 |
| Net margin | 0.7% | -3.4% | 2.0% | 1.8% | 0.8% | 1.1% | 1.6% | 1.8% | 1.5% | 1.7% | 1.4% |
| ROIC | — | -19.8% | 5.3% | 4.9% | 1.8% | 2.6% | 4.5% | 4.8% | 5.4% | 7.3% | 9.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 18 analysts is $75.39, 6% above the current price; targets range from $62.00 to $87.00; the consensus rating is “Buy”; expected EPS is $5.28 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Centene’s P/E ratio?
About 24.4, based on the last twelve months of diluted earnings per share (forward P/E about 14.2).
Is Centene stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 14% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Centene pay a dividend?
Not currently.
Is Centene a good stock to buy?
We do not give buy or sell advice. Centene scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.